- Conditions
- High-grade Glioma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
- Biological
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 4 Years to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2045
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 349
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Glioblastoma, Gliosarcoma, Malignant Gliomas
- Interventions
- lenalidomide, Radiation
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Charlottesville, Virginia
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Laboratory Biomarker Analysis, Montanide ISA 51 VG, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide
- Other · Drug · Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Buffalo, New York • Cleveland, Ohio
- Conditions
- Glioblastoma Multiforme
- Interventions
- CT-322, Temozolomide, Radiation Therapy
- Drug · Procedure
- Lead sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Chicago, Illinois • Lexington, Kentucky + 3 more
- Conditions
- Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Oligodendroglial Tumors, Adult Pineoblastoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)
- Interventions
- radiation therapy, temozolomide, plerixafor, laboratory biomarker analysis, pharmacological study
- Radiation · Drug · Other
- Lead sponsor
- Lawrence Recht
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Glioblastoma Multiforme
- Interventions
- Nivolumab, Temozolomide
- Drug
- Lead sponsor
- University of Sydney
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- prinomastat, temozolomide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- tamoxifen citrate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 237
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more
- Conditions
- Glioblastoma, IDH-wildtype
- Interventions
- Ropidoxuridine
- Drug
- Lead sponsor
- Shuttle Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Miami, Florida • Hackensack, New Jersey + 3 more
- Conditions
- Brain Cancer
- Interventions
- IMPT, IMRT, Cognitive Tests, Questionnaires
- Radiation · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, GBM, Glioma, Malignant, Glioblastoma Multiforme of Brain
- Interventions
- Niraparib, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Nader Sanai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Not listed
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- Up to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 8
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 5 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- dalteparin, radiation therapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 12
- States / cities
- Tampa, Florida • Urbana, Illinois • Kalamazoo, Michigan + 8 more
- Conditions
- Glioblastoma
- Interventions
- CC-90010, Temozolomide, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Glioblastoma
- Interventions
- GammaTile®, External Beam Radiation Therapy, Temozolomide
- Device · Radiation · Drug
- Lead sponsor
- GT Medical Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 766 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Neptune City, New Jersey • Valhalla, New York + 3 more
- Conditions
- Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
- Interventions
- Biospecimen Collection, Magnetic Resonance Imaging, Navtemadlin, Radiation Therapy
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 6 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- poly ICLC, temozolomide, radiation therapy
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Glioblastoma
- Interventions
- CMV-ALT + CMV-DCs, CMV-ALT + Saline
- Biological
- Lead sponsor
- John Sampson
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Glioblastoma
- Interventions
- Bevacizumab, Temozolomide, Radiation therapy, Placebo
- Drug · Radiation
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 921 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Leukemia, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- psychosocial assessment and care
- Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2005
- U.S. locations
- 26
- States / cities
- Sacramento, California • Gainesville, Florida • Miami, Florida + 23 more
- Conditions
- Brain Tumor, Central Nervous System Tumor
- Interventions
- lomustine, temozolomide
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 206
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Glioblastoma
- Interventions
- CART-EGFR-IL13Ra2 cells, Rituximab or Rituximab biosimilar, Fludarabine + Cyclophosphamide combination
- Drug · Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Newly Diagnosed and Recurrent Glioblastoma
- Interventions
- [177Lu]Lu-NeoB, [68Ga]Ga-NeoB, Temozolomide
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more
- Conditions
- Glioblastoma, Glioblastoma Multiforme
- Interventions
- External beam radiation therapy
- Radiation
- Lead sponsor
- John M. Buatti
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa